---
schema_version: "secwatch.filing_event.v1"
accession: "0001110803-25-000057"
form_type: "8-K"
ticker: "ILMN"
cik: "0001110803"
company_name: "ILLUMINA, INC."
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:09:09.461321+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Illumina Q2 EPS $1.19 non-GAAP, revenue $1.06B; raises FY2025 guidance

## Summary
- Revenue $1.059B down 3% YoY; GAAP EPS $1.49, non-GAAP EPS $1.19 vs. $1.09 prior year.
- FY2025 guidance raised: revenue decline (2.5%)-(0.5%), non-GAAP op margin 22%-22.5%, EPS $4.45-$4.55.
- Repurchased 4.5M shares for $380M at avg $84.66; ~$800M remaining authorization.
- Signed definitive agreement to acquire SomaLogic from Standard BioTools; close expected H1 2026.
- Q2 free cash flow $204M; cash and short-term investments $1.16B.

## SEC filing metadata
- accession: 0001110803-25-000057
- form_type: 8-K
- ticker: ILMN
- cik: 0001110803
- company_name: ILLUMINA, INC.
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1110803/000111080325000057/0001110803-25-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1110803/000111080325000057/ilmn-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001110803-25-000057
- JSON: https://secwatch.observer/filing/0001110803-25-000057.json
- Plain text: https://secwatch.observer/filing/0001110803-25-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.